STENTYS | 2,997 followers on LinkedIn | STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex artery disease. STENTYS’ SelfApposing® drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents.
Looking for a particular STENTYS employee's phone or email?
The STENTYS annual revenue was $9 million in 2026.
Lottin Christophe is the CEO of STENTYS.
2 people are employed at STENTYS.
STENTYS is based in Paris, Ile-de-France.
The NAICS codes for STENTYS are [339, 33].
The SIC codes for STENTYS are [384, 38].